Canada markets open in 4 hours 28 minutes
  • S&P/TSX

    17,358.21
    +61.28 (+0.35%)
     
  • S&P 500

    3,669.01
    +6.56 (+0.18%)
     
  • DOW

    29,883.79
    +59.87 (+0.20%)
     
  • CAD/USD

    0.7732
    -0.0010 (-0.13%)
     
  • CRUDE OIL

    44.89
    -0.39 (-0.86%)
     
  • BTC-CAD

    24,972.88
    +494.80 (+2.02%)
     
  • CMC Crypto 200

    378.88
    +13.96 (+3.83%)
     
  • GOLD FUTURES

    1,840.90
    +10.70 (+0.58%)
     
  • RUSSELL 2000

    1,838.03
    +1.98 (+0.11%)
     
  • 10-Yr Bond

    0.9480
    0.0000 (0.00%)
     
  • NASDAQ futures

    12,479.00
    +24.75 (+0.20%)
     
  • VOLATILITY

    21.15
    +0.38 (+1.83%)
     
  • FTSE

    6,434.86
    -28.53 (-0.44%)
     
  • NIKKEI 225

    26,809.37
    +8.39 (+0.03%)
     
  • CAD/EUR

    0.6380
    -0.0007 (-0.11%)
     

ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Reata Pharmaceuticals, Inc. Investors of Important Deadline in Securities Class Action; Encourages Investors with Losses in Excess of $100K to Contact the Firm – RETA

·3 min read

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Reata Pharmaceuticals, Inc. (NASDAQ: RETA) between October 15, 2019 and August 7, 2020, inclusive (the "Class Period"), of the important December 14, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Reata investors under the federal securities laws.

To join the Reata class action, go to http://www.rosenlegal.com/cases-register-1970.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the MOXIe Part 2 study results were insufficient to support a single study marketing approval of omaveloxolone for the treatment of Friedreich’s ataxia ("FA") in the U.S. without additional evidence; (2) as a result, it was foreseeably likely that the FDA would not accept marketing approval of omaveloxolone for the treatment of FA in the U.S. based on the MOXIe Part 2 study results; and (3) as a result, Reata’s public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than December 14, 2020. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-register-1970.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at pkim@rosenlegal.com or cases@rosenlegal.com.

NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. AN INVESTOR’S ABILITY TO SHARE IN ANY POTENTIAL FUTURE RECOVERY IS NOT DEPENDENT UPON SERVING AS LEAD PLAINTIFF.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 3 each year since 2013. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm’s attorneys are ranked and recognized by numerous independent and respected sources. Rosen Law Firm has secured hundreds of millions of dollars for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201026005851/en/

Contacts

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com